MedKoo Cat#: 562452 | Name: HPCG

Description:

WARNING: This product is for research use only, not for human or veterinary use.

HPCG is a HIF-1α prolyl hydroxylase inhibitor.

Chemical Structure

HPCG
HPCG
CAS#3458-69-3

Theoretical Analysis

MedKoo Cat#: 562452

Name: HPCG

CAS#: 3458-69-3

Chemical Formula: C8H8N2O4

Exact Mass: 196.0484

Molecular Weight: 196.16

Elemental Analysis: C, 48.98; H, 4.11; N, 14.28; O, 32.62

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
HPCG;
IUPAC/Chemical Name
N-[(3-Hydroxy-2-pyridinyl)carbonyl]-glycine
InChi Key
IZQMRNMMPSNPJM-UHFFFAOYSA-N
InChi Code
InChI=1S/C8H8N2O4/c11-5-2-1-3-9-7(5)8(14)10-4-6(12)13/h1-3,11H,4H2,(H,10,14)(H,12,13)
SMILES Code
O=C(O)CNC(C1=NC=CC=C1O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 196.16 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Gun'ko VM, Turov VV, Zarko VI, Goncharuk OV, Pakhlov EM, Skubiszewska-Zięba J, Blitz JP. Interfacial phenomena at a surface of individual and complex fumed nanooxides. Adv Colloid Interface Sci. 2016 Sep;235:108-189. doi: 10.1016/j.cis.2016.06.003. Epub 2016 Jun 11. Review. PubMed PMID: 27344189. 2: Mozaffary A, Asgari S, Tohidi M, Kazempour-Ardebili S, Azizi F, Hadaegh F. Change in fasting plasma glucose and incident type 2 diabetes mellitus: results from a prospective cohort study. BMJ Open. 2016 May 23;6(5):e010889. doi: 10.1136/bmjopen-2015-010889. PubMed PMID: 27217283; PubMed Central PMCID: PMC4885425. 3: Watanabe T, Miyao M, Honda R, Yamada Y. Hiroshima survivors exposed to very low doses of A-bomb primary radiation showed a high risk for cancers. Environ Health Prev Med. 2008 Sep;13(5):264-70. doi: 10.1007/s12199-008-0039-8. Epub 2008 Jul 5. Erratum in: Environ Health Prev Med. 2009 May;14(3):209. PubMed PMID: 19568913; PubMed Central PMCID: PMC2698250. 4: Ayres CG, Griffith HM. Consensus guidelines: improving the delivery of clinical preventive services. Health Care Manage Rev. 2008 Oct-Dec;33(4):300-7. doi: 10.1097/01.HCM.0000318767.36901.0b. PubMed PMID: 18815495. 5: Izumi A, Rea D, Adachi T, Unzai S, Park SY, Roper DI, Tame JR. Structure and mechanism of HpcG, a hydratase in the homoprotocatechuate degradation pathway of Escherichia coli. J Mol Biol. 2007 Jul 27;370(5):899-911. Epub 2007 May 10. PubMed PMID: 17559873. 6: Adachi T, Izumi A, Rea D, Park SY, Tame JR, Roper DI. Expression, purification and crystallization of 2-oxo-hept-4-ene-1,7-dioate hydratase (HpcG) from Escherichia coli C. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2006 Oct 1;62(Pt 10):1010-2. Epub 2006 Sep 30. PubMed PMID: 17012798; PubMed Central PMCID: PMC2225172. 7: Sahay TB, Ashbury FD, Roberts M, Rootman I. Effective components for nutrition interventions: a review and application of the literature. Health Promot Pract. 2006 Oct;7(4):418-27. Epub 2006 Aug 23. Review. PubMed PMID: 16928989. 8: Cohen M, Rúa EC, Balcarce N, Drut R. Histologic findings in "ex- Helicobacter pylori" gastric biopsies of pediatric patients. Pediatr Dev Pathol. 2005 Jul-Aug;8(4):420-6. Epub 2005 Jul 14. PubMed PMID: 16010501. 9: Cohen M, Drut R, Cueto Rúa E. SIALYL-Tn antigen distribution in Helicobacter pylori chronic gastritis in children: an immunohistochemical study. Pediatr Pathol Mol Med. 2003 Mar-Apr;22(2):117-29. PubMed PMID: 12556292. 10: Cohen MC, Cueto Rúa E, Balcarce N, Quijano G, Drut R. [Focal atrophy with stellate scars in children with chronic gastritis associated to Helicobacter pylori. Is this early atrophic gastritis?]. Acta Gastroenterol Latinoam. 2001;31(5):411-6. Spanish. PubMed PMID: 11873671. 11: Roper DI, Stringfellow JM, Cooper RA. Sequence of the hpcC and hpcG genes of the meta-fission homoprotocatechuic acid pathway of Escherichia coli C: nearly 40% amino-acid identity with the analogous enzymes of the catechol pathway. Gene. 1995 Apr 14;156(1):47-51. PubMed PMID: 7737515.